-
Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial
Tuesday, April 10, 2018 - 9:36am | 450Read More...vTv Therapeutics Inc (NASDAQ: VTVT) announced Monday after the close that results from Part A of its late-stage study of an investigational medication to treat Alzheimer's disease did not meet either co-primary endpoint. Patients taking its pipeline candidate azeliragon, when compared with a...
-
Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy
Thursday, February 22, 2018 - 11:33am | 345Read More...The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s prospects. But the generic drug developer scored one new advocate Thursday on the basis of its pipeline potential. The Rating Stifel Nicolaus analyst Alex Schwartz upgraded Momenta from Hold to Buy and...
-
Molecular Biology Firm Intrexon Is Close To Generating 'Significant' Product Revenue
Monday, September 21, 2015 - 2:02pm | 350Read More...In a report issued Monday, Stifel initiated coverage of Intrexon Corp (NYSE: XON) with a Buy rating. Analysts Thomas Shrader and Alex Schwartz set a price target of $69.00 for the stock. Shares of the mid-cap company are down more than 5 percent on Monday's trading. According to the...
